MCID: CHR417
MIFTS: 66

Chronic Graft Versus Host Disease

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Chronic Graft Versus Host Disease

Summaries for Chronic Graft Versus Host Disease

NIH Rare Diseases : 54 Chronic graft versus host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms may include skin rash, mouth sores, dry eyes, liver inflammation, development of scar tissue in the skin and joints, and damage to the lungs. The exact cause of chronic GVHD is unknown. It likely results from a complex immune-mediated interaction between the donor and recipient cells. Chronic GVHD is treated with prednisone or other similar anti-inflammatory or immunosuppressive medications.  

MalaCards based summary : Chronic Graft Versus Host Disease, also known as chronic graft-versus-host disease, is related to graft-versus-host disease and hematopoietic stem cell transplantation. An important gene associated with Chronic Graft Versus Host Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Decitabine and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are poor wound healing and intermittent generalized erythematous papular rash

Related Diseases for Chronic Graft Versus Host Disease

Diseases in the Graft-Versus-Host Disease family:

Acute Graft Versus Host Disease Chronic Graft Versus Host Disease

Diseases related to Chronic Graft Versus Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 392)
# Related Disease Score Top Affiliating Genes
1 graft-versus-host disease 32.0 IFNG IL10 IL1A TNF
2 hematopoietic stem cell transplantation 31.4 IFNG IL10 TNF
3 bronchiolitis 30.9 IFNG IL10 TNF
4 bronchiolitis obliterans 30.8 IFNG IL10 TNF
5 erythema multiforme 30.5 IFNG TNF
6 large granular lymphocyte leukemia 30.3 IFNG IL2RA
7 scabies 30.2 IL10 IL1A
8 meningitis 30.2 IFNG IL10 TNF
9 acute graft versus host disease 30.2 IFNG IL10 IL2RA TNF
10 myasthenia gravis 30.2 IFNG IL10 TNF TNFSF13B
11 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.2 IFNG IL10 TNFSF13B
12 myeloma, multiple 30.0 CD79A TNF TNFSF13B
13 colitis 30.0 IFNG IL10 TNF
14 hepatitis a 30.0 IFNG IL10 TNF
15 aspergillosis 30.0 IFNG IL10 TNF
16 sarcoidosis 1 29.9 IFNG IL2RA TNF
17 autoimmune disease 29.8 IFNG IL10 IL2RA TNF TNFSF13B
18 keratoconjunctivitis sicca 29.8 CD79A IL10 IL1A TNF
19 systemic lupus erythematosus 29.8 CD79A IFNG IL10 IL2RA TNF TNFSF13B
20 hemophagocytic lymphohistiocytosis 29.7 IFNG IL10 IL2RA TNF
21 multiple sclerosis 29.6 IFNG IL10 IL2RA TNF TNFSF13B
22 alopecia areata 29.5 IFNG IL1A IL2RA TNF
23 osteoporosis 29.4 CD36 IFNG IL1A TNF
24 arthritis 29.3 IFNG IL10 IL1A MICA TNF
25 uveitis 29.3 IFNG IL10 IL1A IL2RA TNF
26 rheumatoid arthritis 29.0 IFNG IL10 IL1A IL2RA TNF TNFSF13B
27 leukemia 10.7
28 polymyositis 10.5
29 buruli ulcer 10.4 IFNG IL10
30 hand, foot and mouth disease 10.4 IFNG IL10
31 fascioliasis 10.4 IFNG IL10
32 primary peritoneal carcinoma 10.4 IFNG IL10
33 hepatitis 10.4
34 cryptococcal meningitis 10.4 IFNG TNFSF13B
35 lipoid nephrosis 10.4 CD79A IL10
36 lichen planus 10.4
37 milk allergy 10.4 CD79A IL10
38 spondylocarpotarsal synostosis syndrome 10.4
39 cephalosporin allergy 10.4 IFNG IL10
40 folliculitis 10.4 IFNG IL2RA
41 lymphocytic leukemia 10.4
42 nephrotic syndrome 10.4
43 nickel allergic contact dermatitis 10.3 IFNG IL10
44 baylisascariasis 10.3 IFNG IL10
45 bacterial sepsis 10.3 IL10 TNF
46 autoimmune disease of eyes, ear, nose and throat 10.3 IL10 TNF
47 panuveitis 10.3 IL10 TNF
48 scrub typhus 10.3 IL10 TNF
49 lacrimal apparatus disease 10.3 IL10 TNF
50 transverse myelitis 10.3 IL10 TNF

Graphical network of the top 20 diseases related to Chronic Graft Versus Host Disease:



Diseases related to Chronic Graft Versus Host Disease

Symptoms & Phenotypes for Chronic Graft Versus Host Disease

Human phenotypes related to Chronic Graft Versus Host Disease:

60 33 (show top 50) (show all 54)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 poor wound healing 60 33 hallmark (90%) Very frequent (99-80%) HP:0001058
2 intermittent generalized erythematous papular rash 60 33 hallmark (90%) Very frequent (99-80%) HP:0007432
3 photophobia 60 33 frequent (33%) Frequent (79-30%) HP:0000613
4 nail dystrophy 60 33 frequent (33%) Frequent (79-30%) HP:0008404
5 elevated hepatic transaminase 60 33 frequent (33%) Frequent (79-30%) HP:0002910
6 alopecia 60 33 frequent (33%) Frequent (79-30%) HP:0001596
7 keratoconjunctivitis sicca 60 33 frequent (33%) Frequent (79-30%) HP:0001097
8 xerostomia 60 33 frequent (33%) Frequent (79-30%) HP:0000217
9 recurrent infections 60 33 frequent (33%) Frequent (79-30%) HP:0002719
10 erythema 60 33 frequent (33%) Frequent (79-30%) HP:0010783
11 abnormality of skin pigmentation 60 33 frequent (33%) Frequent (79-30%) HP:0001000
12 bronchiectasis 60 33 frequent (33%) Frequent (79-30%) HP:0002110
13 onycholysis 60 33 frequent (33%) Frequent (79-30%) HP:0001806
14 food intolerance 60 33 frequent (33%) Frequent (79-30%) HP:0012537
15 recurrent corneal erosions 60 33 frequent (33%) Frequent (79-30%) HP:0000495
16 muscle weakness 60 33 occasional (7.5%) Occasional (29-5%) HP:0001324
17 dysphagia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002015
18 arthritis 60 33 occasional (7.5%) Occasional (29-5%) HP:0001369
19 flexion contracture 60 33 occasional (7.5%) Occasional (29-5%) HP:0001371
20 gastroesophageal reflux 60 33 occasional (7.5%) Occasional (29-5%) HP:0002020
21 arthralgia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002829
22 dyspnea 60 33 occasional (7.5%) Occasional (29-5%) HP:0002094
23 ascites 60 33 occasional (7.5%) Occasional (29-5%) HP:0001541
24 pancytopenia 60 33 occasional (7.5%) Occasional (29-5%) HP:0001876
25 abdominal pain 60 33 occasional (7.5%) Occasional (29-5%) HP:0002027
26 weight loss 60 33 occasional (7.5%) Occasional (29-5%) HP:0001824
27 skin ulcer 60 33 occasional (7.5%) Occasional (29-5%) HP:0200042
28 anorexia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002039
29 myalgia 60 33 occasional (7.5%) Occasional (29-5%) HP:0003326
30 hematuria 60 33 occasional (7.5%) Occasional (29-5%) HP:0000790
31 chest pain 60 33 occasional (7.5%) Occasional (29-5%) HP:0100749
32 diarrhea 60 33 occasional (7.5%) Occasional (29-5%) HP:0002014
33 cough 60 33 occasional (7.5%) Occasional (29-5%) HP:0012735
34 skin vesicle 60 33 occasional (7.5%) Occasional (29-5%) HP:0200037
35 pneumothorax 60 33 occasional (7.5%) Occasional (29-5%) HP:0002107
36 nausea 60 33 occasional (7.5%) Occasional (29-5%) HP:0002018
37 pleural effusion 60 33 occasional (7.5%) Occasional (29-5%) HP:0002202
38 pulmonary infiltrates 60 33 occasional (7.5%) Occasional (29-5%) HP:0002113
39 fasciitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0100537
40 esophageal ulceration 60 33 occasional (7.5%) Occasional (29-5%) HP:0004791
41 obstructive lung disease 60 33 occasional (7.5%) Occasional (29-5%) HP:0006536
42 urinary bladder inflammation 60 33 occasional (7.5%) Occasional (29-5%) HP:0100577
43 phimosis 60 33 occasional (7.5%) Occasional (29-5%) HP:0001741
44 esophageal stricture 60 33 occasional (7.5%) Occasional (29-5%) HP:0002043
45 wheezing 60 33 occasional (7.5%) Occasional (29-5%) HP:0030828
46 morphea 60 33 occasional (7.5%) Occasional (29-5%) HP:0012344
47 bronchiolitis obliterans 60 33 occasional (7.5%) Occasional (29-5%) HP:0011946
48 entrapment neuropathy 60 33 occasional (7.5%) Occasional (29-5%) HP:0012181
49 abnormal vagina morphology 33 occasional (7.5%) HP:0000142
50 pain 60 Occasional (29-5%)

GenomeRNAi Phenotypes related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased caspase 3/7 activity GR00318-A 8.8 CD4 MICA TNFSF13B

MGI Mouse Phenotypes related to Chronic Graft Versus Host Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.02 CD36 CD4 CD79A IFNG IL10 IL1A
2 homeostasis/metabolism MP:0005376 9.92 CD36 CD4 CD79A IFNG IL10 IL1A
3 digestive/alimentary MP:0005381 9.91 CD36 CD4 IFNG IL10 IL2RA TNF
4 immune system MP:0005387 9.91 CD36 CD4 CD79A IFNG IL10 IL1A
5 endocrine/exocrine gland MP:0005379 9.88 CD36 CD4 IFNG IL10 IL2RA TNF
6 liver/biliary system MP:0005370 9.55 CD36 CD79A IFNG IL10 TNF
7 neoplasm MP:0002006 9.35 CD79A IFNG IL10 IL1A TNF
8 no phenotypic analysis MP:0003012 9.02 CD4 CD79A IFNG IL10 TNF

Drugs & Therapeutics for Chronic Graft Versus Host Disease

Drugs for Chronic Graft Versus Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 369)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2353-33-5 451668
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
3
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
4
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
5
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2 179045-86-4, 152923-56-3
6
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 143 6006
7
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 104987-11-3 6473866 445643 439492
8
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
9
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
10
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 147-94-4, 65-46-3 6253
11
Foscarnet Approved Phase 4,Phase 2 4428-95-9, 63585-09-1 3415
12
Ganciclovir Approved, Investigational Phase 4,Phase 2,Not Applicable 82410-32-0 3454
13
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
14
Infliximab Approved Phase 4,Phase 3,Phase 2 170277-31-3
15
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 27284 23925
16
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381
17
Lomustine Approved, Investigational Phase 4,Phase 2,Phase 3 13010-47-4 3950
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59-30-3 6037
19
Phosphonoacetic Acid Experimental Phase 4,Phase 2 4408-78-0 546
20
Treosulfan Investigational Phase 4,Phase 3,Phase 2,Phase 1 299-75-2 9296
21
Semustine Experimental, Investigational Phase 4,Phase 2,Phase 3 13909-09-6
22 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
25 Vitamin B9 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Cyclosporins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
27 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
28 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
29 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
32 Vitamin B Complex Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
34 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
35 Calcineurin Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
36 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Folic Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 Folate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
40 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Thymoglobulin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Anti-Retroviral Agents Phase 4,Phase 2,Phase 1
45 Reverse Transcriptase Inhibitors Phase 4,Phase 2
46 Ganciclovir triphosphate Phase 4,Phase 2,Not Applicable
47 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Iron Chelating Agents Phase 4
50 Chelating Agents Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 926)
# Name Status NCT ID Phase Drugs
1 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
2 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Unknown status NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
3 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
4 Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor Completed NCT02660684 Phase 4 Prograf;Methotrexate;Cyclosporine
5 Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload Completed NCT01335035 Phase 4 deferasirox
6 ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
7 Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis Recruiting NCT01856803 Phase 4 anti thymoglobulin
8 CMV-CTL for the Treatment of CMV Infection After HSCT Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
9 Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major Recruiting NCT03171831 Phase 4 Busulfan;Cyclophosphamide;Fludarabine;Mycophenolate mofetil;Tacrolimus;Methotrexate;Thymoglobulin;Basiliximab
10 ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
11 ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center Recruiting NCT03608059 Phase 4 ATG/PTCy;standard ATG;standard PTCy
12 PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Recruiting NCT03689465 Phase 4 ATG;CTX;Mycophenolate Mofetil
13 A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT Not yet recruiting NCT03190733 Phase 4 ATG
14 Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Disease Unknown status NCT01526850 Phase 2, Phase 3 Cyclosporine and Glucocorticoid
15 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
16 ALL-SCT BFM International- HSCT in Children and Adolescents With ALL Unknown status NCT01423500 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
17 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
18 Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
19 Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression Unknown status NCT02178683 Phase 3 Tacrolimus and MMF.
20 Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia Unknown status NCT01145976 Phase 3 Cy-ATG;Flu-ATG
21 MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD Unknown status NCT02241018 Phase 2, Phase 3 CD25 monoclonal antibody;calcineurin inhibitors
22 Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma Unknown status NCT00998270 Phase 2, Phase 3
23 Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis Unknown status NCT01238328 Phase 2, Phase 3 Conditioning regimen;Graft-versus-host disease (GVHD) prophylaxis
24 Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis Unknown status NCT01087398 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen);Cyclosporin, Methotrexate (GVHD prophylaxis)
25 MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment Unknown status NCT02240992 Phase 2, Phase 3
26 The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
27 TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID Unknown status NCT02327351 Phase 2, Phase 3
28 Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia Unknown status NCT00342316 Phase 3
29 Haplo-SCT vs ASCT With or Without Decitabine in AML CR1 Unknown status NCT02059720 Phase 3
30 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
31 Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Completed NCT01106833 Phase 2, Phase 3 Sirolimus + calcineurin inhibitor + prednisone;Sirolimus + prednisone
32 Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia Completed NCT00678275 Phase 3 ATG FRESENIUS (Anti-Lymphocyte-Globulin);ATG FRESENIUS (Anti-Lymphocyte-Globulin)
33 Clinical Trial With Clobetasol and Dexamethasone for Topical Treatment of Oral Lesions of Chronic Graft-versus-host Disease Completed NCT01699412 Phase 3 Clobetasol;Dexamethasone
34 Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) Completed NCT01295710 Phase 3
35 Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease Completed NCT00031824 Phase 3 cyclosporine;hydroxychloroquine;prednisone;tacrolimus
36 Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML Completed NCT01191957 Phase 3 Busulphan plus Cyclophosphamide;Busulphan plus Fludarabine
37 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
38 Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation Completed NCT01020175 Phase 3
39 Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD) Completed NCT00887263 Phase 3 Budesonide;Placebo
40 T-Cell Depletion in Unrelated Donor Marrow Transplantation Completed NCT00000591 Phase 3
41 Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT) Completed NCT00330018 Phase 3 Valganciclovir;Acyclovir
42 Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation Completed NCT00130754 Phase 3 Thymoglobuline
43 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
44 Nonmyeloablative Stem Cell Transplant in Elderly Completed NCT00382759 Phase 2, Phase 3
45 Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation Completed NCT01530581 Phase 3
46 Stem Cell Transplant for Bone Marrow Failure Syndromes Completed NCT00176878 Phase 2, Phase 3 Fludarabine monophosphate;Busulfan
47 Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA Completed NCT00455312 Phase 2, Phase 3 Campath 1H;Cyclophosphamide;Fludarabine;antithymocyte globulin;Methylprednisolone
48 Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies Completed NCT00275678 Phase 3
49 Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients Completed NCT00411645 Phase 3 maribavir
50 Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Completed NCT00075816 Phase 3

Search NIH Clinical Center for Chronic Graft Versus Host Disease

Genetic Tests for Chronic Graft Versus Host Disease

Anatomical Context for Chronic Graft Versus Host Disease

MalaCards organs/tissues related to Chronic Graft Versus Host Disease:

42
T Cells, Bone, Bone Marrow, Myeloid, Skin, B Cells, Lung

Publications for Chronic Graft Versus Host Disease

Articles related to Chronic Graft Versus Host Disease:

(show top 50) (show all 1432)
# Title Authors Year
1
The benefit of chronic graft-versus-host disease in patients with acute myeloid leukemia relapsed after allogeneic stem cell transplantation. ( 30993416 )
2019
2
Chronic graft-versus-host disease and the risk of primary disease relapse; a meta-analysis. ( 31047963 )
2019
3
Refractory inflammatory myopathy in hematopoietic stem cell transplant patients with chronic graft-versus-host disease: report of two cases. ( 31053488 )
2019
4
Blaschkolinear Lichen Planus Pigmentosus in the Setting of Chronic Graft-versus-host Disease. ( 30328472 )
2019
5
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease. ( 30337698 )
2019
6
Quantitative Assessment of Liver Stiffness Using Ultrasound Shear Wave Elastography in Patients With Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Pilot Study. ( 30352484 )
2019
7
Community-acquired Disseminated Exophiala dermatitidis Mycosis with Necrotizing Fasciitis in Chronic Graft-versus-host Disease. ( 30449799 )
2019
8
GM-CSF therapy inhibits chronic graft-versus-host disease via expansion of regulatory T cells. ( 30457669 )
2019
9
Treatment with apremilast was beneficial for chronic graft-versus-host disease skin lesion in a patient with psoriasis. ( 30632183 )
2019
10
A confirmation of chronic graft-versus-host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation. ( 30655371 )
2019
11
How I treat refractory chronic graft-versus-host disease. ( 30674472 )
2019
12
Dermatology Impact on the Care of Children with Chronic Graft-versus-Host Disease of the Skin. ( 30677461 )
2019
13
Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition. ( 30697701 )
2019
14
The management of numerous carcinomatous sequelae of human papilloma virus in an allogeneic stem cell transplant patient with chronic graft versus host disease. ( 30733986 )
2019
15
Invasive fungal disease is associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplant: a single center, retrospective study. ( 30734248 )
2019
16
Targeting PI3Kδ Function For Amelioration of Murine Chronic Graft-Versus-Host Disease. ( 30748099 )
2019
17
Oral rehabilitation in a patient with sclerotic-phenotype chronic graft versus host disease: a case report. ( 30773573 )
2019
18
Female genital tract chronic graft-versus-host disease: A narrative review. ( 30793107 )
2019
19
Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. ( 30296479 )
2019
20
Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. ( 30279226 )
2019
21
Double-Negative T Cell Levels Correlate with Chronic Graft-versus-Host Disease Severity. ( 30244108 )
2019
22
Characterization of Late Acute and Chronic Graft-Versus-Host Disease according to the 2014 National Institutes of Health Consensus Criteria in Japanese Patients. ( 30244104 )
2019
23
Machine learning reveals chronic graft-versus-host disease phenotypes and stratifies survival after stem cell transplant for hematologic malignancies. ( 30237265 )
2019
24
The Anatomic Distribution of Skin Involvement in Patients with Incident Chronic Graft-versus-Host Disease. ( 30219700 )
2019
25
Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease. ( 30201397 )
2019
26
Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients. ( 30089900 )
2019
27
Chronic graft-versus-host disease: Current management paradigm and future perspectives. ( 29984442 )
2019
28
Longitudinal follow-up of response status and concomitant immunosuppression in patients treated with extracorporeal photopheresis for chronic graft versus host disease. ( 29740177 )
2019
29
Early initiation of extracorporeal photochemotherapy increases response for chronic graft versus host disease following steroid failure. ( 29655590 )
2019
30
Lipocalin-2 Levels in Acute and Chronic Graft-versus-Host Disease following Allogeneic Haematopoietic Stem Cell Transplantation. ( 31078634 )
2019
31
Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation-a retrospective analysis on seven patients. ( 30993415 )
2019
32
Clinical features of chronic graft-versus-host disease following haploidentical transplantation combined with infusion of a cord blood. ( 30977441 )
2019
33
A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease. ( 30955381 )
2019
34
Clinical and Dermoscopic Evaluation of Melanocytic Lesions in Patients with Chronic Graft Versus Host Disease. ( 30938827 )
2019
35
Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. ( 30936059 )
2019
36
Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. ( 30936057 )
2019
37
Humanistic burden of patients with chronic graft-versus-host disease - systematic literature review of health-related quality of life and functional status. ( 30925855 )
2019
38
Expansion of circulating extrafollicular helper T-like cells in patients with chronic graft-versus-host disease. ( 30878167 )
2019
39
Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland. ( 30876928 )
2019
40
B Cells in Chronic Graft-versus-Host Disease. ( 30849450 )
2019
41
Longstanding alopecia and nail dystrophy are associated with more severe overall chronic graft-versus-host disease in adults. ( 30214010 )
2019
42
Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. ( 30485788 )
2018
43
Permanent alopecia as a manifestation of chronic graft-versus-host disease of the scalp: clinical, dermoscopic and histopathological observations. ( 29876958 )
2018
44
Bilateral Adrenal Hemorrhage in a Patient with Antiphospholipid Syndrome during Chronic Graft-versus-host Disease. ( 29279512 )
2018
45
Biomarkers in chronic graft-versus-host disease: quo vadis? ( 29367715 )
2018
46
Griscelli Syndrome with Fibronodular Sclerodermatous Chronic Graft Versus Host Disease. ( 29398817 )
2018
47
Chronic graft versus host disease presenting as lichen planus pigmentosus. ( 29410549 )
2018
48
Reprint of: Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease. ( 29425517 )
2018
49
B-cell targeting in chronic graft-versus-host disease. ( 29437591 )
2018
50
TGF-β-Induced CD8+CD103+ Regulatory T Cells Show Potent Therapeutic Effect on Chronic Graft-versus-Host Disease Lupus by Suppressing B Cells. ( 29441062 )
2018

Variations for Chronic Graft Versus Host Disease

Expression for Chronic Graft Versus Host Disease

Search GEO for disease gene expression data for Chronic Graft Versus Host Disease.

Pathways for Chronic Graft Versus Host Disease

Pathways related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 CD36 CD4 CD79A IFNG IL10 IL1A
2
Show member pathways
13.55 CD4 IFNG IL10 IL1A IL2RA TNF
3
Show member pathways
13.42 CD4 IFNG IL10 IL1A IL2RA TNF
4
Show member pathways
13.3 CD4 IL10 IL1A IL2RA TNF TNFSF13B
5
Show member pathways
13.19 CD4 IL10 IL1A IL2RA TNF TNFSF13B
6
Show member pathways
13.14 CD36 CD4 IFNG IL10 IL1A IL2RA
7
Show member pathways
13.09 CD79A IFNG IL1A IL2RA TNF
8
Show member pathways
12.59 CD4 IFNG IL1A TNF
9
Show member pathways
12.53 CD4 CD79A IFNG IL10 IL2RA TNF
10
Show member pathways
12.51 CD4 IFNG IL10 TNF
11
Show member pathways
12.5 CD4 IFNG IL10 IL1A IL2RA MICA
12
Show member pathways
12.49 CD4 IFNG IL10 IL1A TNF
13
Show member pathways
12.42 CD4 IFNG IL10 IL1A IL2RA TNF
14 12.36 CD79A IFNG IL10 IL2RA TNF TNFSF13B
15
Show member pathways
12.21 IFNG IL10 IL1A TNF
16
Show member pathways
12.2 IFNG IL10 IL1A IL2RA TNF
17 12.18 IFNG IL10 IL1A TNF
18
Show member pathways
12.17 CD36 IL1A TNF
19
Show member pathways
12.12 IFNG IL1A TNF
20 12.09 IL10 IL1A TNF
21 12.02 IFNG IL1A TNF
22
Show member pathways
12.01 CD4 IFNG IL10 TNF
23 11.97 IFNG IL1A TNF
24
Show member pathways
11.96 CD36 IFNG TNF
25 11.96 IFNG IL1A TNF TNFSF13B
26
Show member pathways
11.95 CD4 IFNG IL10 IL1A IL2RA TNFSF13B
27 11.93 CD36 IL10 IL1A TNF
28
Show member pathways
11.91 CD4 IFNG IL2RA
29 11.84 IFNG IL10 TNF
30 11.83 IFNG IL1A TNF TNFSF13B
31 11.81 IFNG IL10 IL2RA
32
Show member pathways
11.72 IFNG IL2RA TNF
33 11.72 IL10 IL1A TNF
34 11.72 CD4 IFNG IL10 TNF
35 11.71 CD36 CD4 IL1A IL2RA TNF
36 11.69 CD36 IFNG IL10 TNF
37
Show member pathways
11.63 IFNG IL1A TNF
38
Show member pathways
11.62 IFNG IL2RA TNF
39 11.56 CD4 IFNG IL10 IL2RA TNF
40 11.51 IL10 IL1A TNF
41 11.5 CD36 IFNG IL10 TNF
42 11.47 IFNG IL1A TNF
43 11.44 CD4 IFNG IL10 IL2RA
44 11.36 IFNG IL10 TNF
45 11.33 IL10 IL1A TNF
46 11.24 IFNG IL2RA
47 11.23 CD4 IFNG IL2RA
48 11.23 CD36 CD4 CD79A IFNG IL10 IL2RA
49 11.22 IFNG TNF
50
Show member pathways
11.18 IFNG IL2RA

GO Terms for Chronic Graft Versus Host Disease

Cellular components related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.65 CD36 CD4 IL2RA MICA TNF
2 extracellular space GO:0005615 9.5 CD36 IFNG IL10 IL1A MICA TNF
3 membrane raft GO:0045121 9.46 CD36 CD4 CD79A TNF
4 external side of plasma membrane GO:0009897 9.02 CD36 CD4 CD79A IL2RA TNF

Biological processes related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.93 CD4 CD79A IL2RA TNFSF13B
2 positive regulation of gene expression GO:0010628 9.86 CD36 IFNG IL1A TNF
3 regulation of signaling receptor activity GO:0010469 9.83 IFNG IL10 IL1A TNF TNFSF13B
4 positive regulation of protein phosphorylation GO:0001934 9.79 CD4 IFNG TNF
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.78 CD36 CD4 TNF
6 cellular response to lipopolysaccharide GO:0071222 9.77 CD36 IL10 TNF
7 positive regulation of T cell proliferation GO:0042102 9.69 CD4 IL2RA TNFSF13B
8 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.65 IL1A TNF
9 negative regulation of mitotic cell cycle GO:0045930 9.65 IL10 TNF
10 cell surface receptor signaling pathway GO:0007166 9.65 CD36 CD4 CD79A IFNG IL2RA
11 B cell proliferation GO:0042100 9.64 CD79A IL10
12 negative regulation of interleukin-6 production GO:0032715 9.64 IL10 TNF
13 regulation of synapse organization GO:0050807 9.63 IL10 TNF
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.63 CD36 IFNG TNF
15 positive regulation of interleukin-12 production GO:0032735 9.62 CD36 IFNG
16 positive regulation of protein complex assembly GO:0031334 9.62 IFNG TNF
17 positive regulation of osteoclast differentiation GO:0045672 9.59 IFNG TNF
18 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.58 IFNG TNF
19 regulation of regulatory T cell differentiation GO:0045589 9.58 IFNG IL2RA
20 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.57 IL10 TNF
21 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.55 CD4 IL1A
22 endothelial cell apoptotic process GO:0072577 9.54 IL10 TNF
23 negative regulation of cytokine secretion involved in immune response GO:0002740 9.52 IL10 TNF
24 positive regulation of cytokine secretion GO:0050715 9.5 IL10 IL1A TNF
25 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 IFNG TNF
26 receptor biosynthetic process GO:0032800 9.48 IL10 TNF
27 cytokine-mediated signaling pathway GO:0019221 9.43 CD36 CD4 IL10 IL1A IL2RA TNF
28 positive regulation of blood microparticle formation GO:2000334 9.4 CD36 TNF
29 positive regulation of vitamin D biosynthetic process GO:0060557 9.37 IFNG TNF
30 negative regulation of growth of symbiont in host GO:0044130 9.33 CD36 IL10 TNF
31 immune response GO:0006955 9.28 CD36 CD4 IFNG IL10 IL1A IL2RA

Molecular functions related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.65 CD36 CD4 CD79A IFNG IL10 IL1A
2 tumor necrosis factor receptor binding GO:0005164 9.16 TNF TNFSF13B
3 cytokine activity GO:0005125 9.02 IFNG IL10 IL1A TNF TNFSF13B

Sources for Chronic Graft Versus Host Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....